Abstract
Tacrolimus is an important therapy in the post-transplant immunosuppressant regimen. However, it is responsible for the highest incidence of a specific type of diabetes called new onset diabetes after transplantation (NODAT). The dangers of NODAT are not limited to cardiovascular or nerve diseases, but also to kidney complication that may lead to loss of transplant kidney. The aim of this article is to discuss the possible theory of NODAT induces by tacrolimus and its common therapy. In addition, this research is to enhance knowledge about the pharmacokinetic and dynamic of tacrolimus. This review depends on research in reliable and popular medical databases which are PubMed, Google Scholar, Saudi Digital Library, and Web of Science (ISI). While the terms used to search the published researches are organ transplantation, immunosuppressant, tacrolimus, new-onset diabetes after transplantation, and hypoglycemic drug.